USPTO serial 88513444
Serial No. 88513444
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 15, 2020
- Examiner
- OPUTA, CHIOMA N
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with Serial No. 88513444?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $1,275
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
3011 Bern, CH
3011 Bern, CH
3011 Bern, CH
GUANGZHOU CITY, GUANGDONG PROVINCE,, CN
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Yue (Robert) Xu
Yue (Robert) Xu APEX ATTORNEYS AT LAW, LLP160 ALAMO PLAZA #942ALAMO, CA 94507United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Proteins for use in the manufacture of food supplements; proteins for the food industry; ] protein for use in the manufacture of cosmetics; protein in raw material form for scientific and medical research; protein for industrial use; [ animal albumen for use in the manufacture of skin care product; animal albumen as a raw material for industrial use; diagnostic preparations other than for medical or veterinary purposes; ] biological preparations for use in industry and science; biological preparation for use in cell cultures other than for medical or veterinary use; cultures of microorganisms, other than for medical and veterinary use; [ chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes; biochemical catalysts; stem cells, other than for medical or veterinary purposes ] | ACTIVE | Feb 20, 2019 |
| 005 | Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-inflammatories, anti-virals, anti-infectives, immunosuppressants and pharmaceutical antibodies; pharmaceuticals, namely, preparations for antibody and antibody-derivative development; pharmaceuticals, namely, antibodies and proteins for the treatment of oncological and autoimmune diseases and disorders; cytokine preparations and antibodies in the nature of pharmaceutical preparations for the treatment of oncological and autoimmune diseases and disorders; pharmaceutical preparations, namely, immuno- therapeutics and cytokines for the treatment of oncological and autoimmune diseases and disorders; diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; medicines for the treatment of gastrointestinal diseases, for human purposes; pharmaceutical products for the prevention and treatment of cancer, for human purposes; tumor suppressing agents, for human purpose; [ pharmaceutical preparations for use in chemotherapy; ] pharmaceutical preparations for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for peripheral nervous system; vaccines; diagnostic preparations for medical purposes; [ chemical preparations for medical purposes, namely, for treating cancer; nutritional supplements; biocides; surgical glues ] | ACTIVE | Feb 20, 2019 |
| 042 | Biological research; medical and scientific research, namely, conducting clinical trials for others; research and development services in the field of antibodies; biotechnology research; testing of pharmaceuticals; analysis of the mode of action of chemical combinations on animals; bacteriological research; scientific laboratory services; scientific research; biomedical research services | ACTIVE | Feb 20, 2019 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CantonBio AG
- Other trademarks owned by CantonBio AG
- Other trademarks owned by CantonBio AG
- Other trademarks owned by CANTONBIO CO., LTD.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 14, 2026 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Nov 14, 2026 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Nov 14, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 14, 2026 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Sep 15, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 3, 2023 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 15, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 14, 2020 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Aug 13, 2020 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jul 24, 2020 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jul 24, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 5, 2020 | IUAF | USE AMENDMENT FILED | — |
| Jul 5, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Feb 18, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 24, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 24, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 4, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 20, 2019 | ALIE | ASSIGNED TO LIE | — |
| Nov 16, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 1, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 31, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 31, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 30, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 30, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 30, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 30, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 20, 2019 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 19, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 17, 2019 | NWAP | NEW APPLICATION ENTERED | — |